Cargando…

Aberrant patterns of PET response during treatment for DLBCL patients with MYC gene rearrangements

PURPOSE: MYC gene rearrangements in diffuse large B-cell lymphoma (DLBCL) patients are associated with poor prognosis. Our aim was to compare patterns of 2[(18)F]fluoro-2-deoxy-D-glucose positron emission tomography computed tomography (PET/CT) response in MYC + and MYC- DLBCL patients. METHODS: Int...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eertink, J. J., Arens, A. I. J., Huijbregts, J. E., Celik, F., de Keizer, B., Stroobants, S., de Jong, D., Wiegers, S. E., Zwezerijnen, G. J. C., Burggraaff, C. N., Boellaard, R., de Vet, H. C. W., Hoekstra, O. S., Lugtenburg, P. J., Chamuleau, M. E. D., Zijlstra, J. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8803795/ https://www.ncbi.nlm.nih.gov/pubmed/34476551 http://dx.doi.org/10.1007/s00259-021-05498-7

Ejemplares similares

Baseline radiomics features and MYC rearrangement status predict progression in aggressive B-cell lymphoma
por: Eertink, Jakoba J., et al.
Publicado: (2022)

Comparing lesion and feature selections to predict progression in newly diagnosed DLBCL patients with FDG PET/CT radiomics features
por: Eertink, Jakoba J., et al.
Publicado: (2022)

Reproducibility of [18F]FDG PET/CT liver SUV as reference or normalisation factor
por: Zwezerijnen, Gerben J. C., et al.
Publicado: (2022)

External validation: a simulation study to compare cross-validation versus holdout or external testing to assess the performance of clinical prediction models using PET data from DLBCL patients
por: Eertink, Jakoba J., et al.
Publicado: (2022)

(18)F-FDG PET baseline radiomics features improve the prediction of treatment outcome in diffuse large B-cell lymphoma
por: Eertink, Jakoba J., et al.
Publicado: (2021)

Baseline PET radiomics outperforms the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma
por: Eertink, J. J., et al.
Publicado: (2023)

Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index
por: Mikhaeel, N. George, et al.
Publicado: (2022)

An artificial intelligence method using FDG PET to predict treatment outcome in diffuse large B cell lymphoma patients
por: Ferrández, Maria C., et al.
Publicado: (2023)

Combatting the effect of image reconstruction settings on lymphoma [(18)F]FDG PET metabolic tumor volume assessment using various segmentation methods
por: Ferrández, Maria C., et al.
Publicado: (2022)

Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter phase II HOVON trial
por: Chamuleau, Martine E.D., et al.
Publicado: (2019)

Sensitivity of an AI method for [(18)F]FDG PET/CT outcome prediction of diffuse large B-cell lymphoma patients to image reconstruction protocols
por: Ferrández, Maria C., et al.
Publicado: (2023)

Optimizing Workflows for Fast and Reliable Metabolic Tumor Volume Measurements in Diffuse Large B Cell Lymphoma
por: Burggraaff, Coreline N., et al.
Publicado: (2020)

A non-randomized risk-adjusted comparison of lenalidomide + R-CHOP versus R-CHOP for MYC-rearranged DLBCL patients
por: de Jonge, A. Vera, et al.
Publicado: (2023)

Blood‐circulating EV‐miRNAs, serum TARC, and quantitative FDG‐PET features in classical Hodgkin lymphoma
por: Drees, Esther E. E., et al.
Publicado: (2022)

No sex differential in relative survival among older patients with DLBCL treated with R-CHOP21: a population-based study
por: Geerdes, Emma E., et al.
Publicado: (2023)

How I treat older patients with DLBCL in the frontline setting
por: Lugtenburg, Pieternella J., et al.
Publicado: (2023)

Molecularly Stratified Treatment Options in Primary Refractory DLBCL/HGBL with MYC and BCL2 or BCL6 Rearrangements (HGBL, NOS with MYC/BCL6)
por: Witte, Hanno M., et al.
Publicado: (2023)

Prognostic model using (18)F-FDG PET radiomics predicts progression-free survival in relapsed/refractory Hodgkin lymphoma
por: Driessen, Julia, et al.
Publicado: (2023)

Predictive value of interim positron emission tomography in diffuse large B-cell lymphoma: a systematic review and meta-analysis
por: Burggraaff, Coreline N., et al.
Publicado: (2018)

Quantitative implications of the updated EARL 2019 PET–CT performance standards
por: Kaalep, Andres, et al.
Publicado: (2019)

Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements
por: McPhail, Ellen D., et al.
Publicado: (2018)

MYC Immunohistochemistry Predicts MYC Rearrangements by FISH
por: Nwanze, Julum, et al.
Publicado: (2017)

Impact of partial-volume correction in oncological PET studies: a systematic review and meta-analysis
por: Cysouw, Matthijs C. F., et al.
Publicado: (2017)

Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients
por: Krull, Jordan E., et al.
Publicado: (2020)

PET segmentation of bulky tumors: Strategies and workflows to improve inter-observer variability
por: Pfaehler, Elisabeth, et al.
Publicado: (2020)

PB2161: CHARACTERISTICS OF AGGRESSIVE B-CELL LYMPHOMAS WITH MYC REARRANGEMENT
por: Ortuzar Pasalodos, A., et al.
Publicado: (2022)

Investigating In Situ Expression of c-MYC and Candidate Ubiquitin-Specific Proteases in DLBCL and Assessment for Peptidyl Disruptor Molecule against c-MYC-USP37 Complex
por: Kamran, Durr e Sameen, et al.
Publicado: (2023)

3D Convolutional Neural Network-Based Denoising of Low-Count Whole-Body (18)F-Fluorodeoxyglucose and (89)Zr-Rituximab PET Scans
por: de Vries, Bart M., et al.
Publicado: (2022)

Anaplastic multiple myeloma with MYC rearrangement
por: Ichikawa, Satoshi, et al.
Publicado: (2021)

Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL coexpressing BCL2 and MYC in the phase 3 PHOENIX trial
por: Johnson, Peter W. M., et al.
Publicado: (2023)

Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit
por: Cucco, Francesco, et al.
Publicado: (2019)

Promiscuous Rearrangements of the MYC Locus Hijack Enhancers and Super-Enhancers to Dysregulate MYC Expression in Multiple Myeloma
por: Affer, Maurizio, et al.
Publicado: (2014)

Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment
por: van der Horst, Hilma J., et al.
Publicado: (2021)

Role of MYC and BCL2 expression in a cohort of 43 patients with DLBCL: a retrospective study
por: Khan, Umair Tahir, et al.
Publicado: (2021)

MYC rearrangement but not extra MYC copies is an independent prognostic factor in patients with mantle cell lymphoma
por: Wang, Lifu, et al.
Publicado: (2020)

The Immunology of DLBCL
por: Takahara, Taishi, et al.
Publicado: (2023)

Guidelines for quality control of PET/CT scans in a multicenter clinical study
por: Hristova, Ivalina, et al.
Publicado: (2017)

Factors that influence treatment decision-making in elderly DLBCL patients: a case vignette study
por: van der Poel, M. W. M., et al.
Publicado: (2015)

P1268: DELINEATING THE NEOANTIGEN BURDEN AND TUMOUR MICROENVIRONMENT IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA (DLBCL).
por: Jiang, Y., et al.
Publicado: (2022)

Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study
por: Kersten, Marie José, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1d8b0ckfkgilofg9d59bl4teg0